Document Classification

Section Type: RESULTS

Text: Least-square mean changes from baseline were greater for both naproxcinod doses compared with placebo at week 13 for WOMAC pain (-31. 3 [standard error 1. 67], -28. 1 [1. 64], and -20. 4 [1. 62] mm with naproxcinod 750 mg bid [P < 0. 0001], 375 mg bid [P = 0. 0008], and placebo, respectively), WOMAC function (-27. 8 [1. 60], -23. 8 [1. 58], and -14. 9 [1. 56] mm, respectively, P < 0. 0001), and patient overall rating of disease status (1. 00 [0. 061], 0. 81 [0. 060], and 0. 49 [0. 059], respectively, P < 0. 0001).